Suspended

The Assessment of Antimicrobial Peptides Against Fungal Infection

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected at a single point in time - Cross-sectional
Who is being recruted

Bacterial Infections and Mycoses

+ Infections

+ Mycoses

From 18 to 70 Years
+3 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Other

Utilizing specific methods not covered by standard models in order to address unique research questions.
Observational
Study Start: December 2022
See protocol details

Summary

Principal SponsorAssiut University
Study Contactsara salah abd el mawgoud, assistant lecturer
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: December 1, 2022

Actual date on which the first participant was enrolled.

Fungal infections are recurrent in the clinical environment and, annually, affect 25% of the general population worldwide, causing high morbidity and mortality rates. The indiscriminate use of broad-spectrum antibiotics, along with parenteral nutrition, permanent catheters, chemotherapy and radiotherapy, as well as immunosuppression in patients, is the most important predisposing factors for invasive fungal infections. Fungi are classified according to their morphologies, including yeasts (Cryptococcus spp.), fungi with branched hyphae (Aspergillus spp.), as well as fungi with both morphologies (yeasts and pseudohyphae, as for Candida spp.), which have all been associated with fungal infections in humans. Fungal biofilms are communities of adherent cells surrounded by an extracellular matrix. These biofilms are commonly found during infection caused by a variety of fungal pathogens. Clinically, biofilm infections can be extremely difficult to eradicate due to their resistance to antifungals and host defenses. Biofilm formation can protect fungal pathogens from many aspects of the innate immune system, including killing by neutrophils and monocytes. Currently, antifungal therapies are scarce and include only four classes of antifungal agents, polyenes, triazoles, echinocandins and flucytosine . The misuse of antifungal agents over the last two decades contributed to antifungal resistance development.Fungal resistance emergence has important clinical implications, as it limits the already small arsenal of antifungal agents, raising the idea of a "post-antifungal" era. Antimicrobial peptides (AMPs) have emerged as new biopharmaceuticals to prevent or treat fungal infections. AMPs are a class of small peptides that widely exist in nature and are an important part of the innate immune system of different organisms. AMPs have a wide range of inhibitory effects against bacteria, fungi, parasites and viruses . Defensins comprise antifungal peptides isolated from various organisms, including plants and mammals . Plant defensins are cationic and have 45-54 amino acids in length. These peptides have typically been isolated from seeds, but can also be found in other plant tissues including leaves, flowers, roots and stems. Most of the plant defensins identified so far have eight cysteine residues that favor structural stability by the formation of four disulfide bonds . In addition, structural studies have shown that plant defensins comprise a triple β-sheet with a parallel helix. Regarding their biological properties, plant defensins have shown activity against bacteria and fungi, both in their planktonic and biofilm modes of growth . Peptides from the cathelicidin family have been isolated from different species of mammals and exhibit broad-spectrum activities against fungi. Cathelicidins are characterized as cationic peptides, consisting of 12-80 amino acids that adopt an α-helix or β-sheet as secondary structures, most of which have 23-37 amino acid residues distributed in amphipathic helices, including LL-37. The activities of LL-37 have been investigated against Candida spp. strains. Human salivary histatins are a group of small histidine-rich proteins constituted from 7 to 38 amino acids first isolated from human parotid saliva. In general, histatins are a multifunctional group of proteins with antimicrobial properties that vary from broad-spectrum to moderate activities. Moreover, histatins have been reported for their effective antifungal activity

Official TitleThe Assessment of Antimicrobial Peptides Against Fungal Infection
NCT05368948
Principal SponsorAssiut University
Study Contactsara salah abd el mawgoud, assistant lecturer
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

100 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Other

Some studies use unique or mixed approaches that don't fit standard categories. These may include innovative observational methods or studies tailored to specific research questions.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 70 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Bacterial Infections and MycosesInfectionsMycoses

Criteria

1 inclusion criteria required to participate
Samples obtained from patients with cutaneous fungal infection and systemic fungal infection

2 exclusion criteria prevent from participating
Patients diagnosed to be viral or bacterial infections.

Patients on antibiotic or antifungal treatment

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
SuspendedNo study centers